Tang Capital Management LLC Reports 0.3% Stake in Altimmune, Inc. (ALT)

On May 15, 2026, Tang Capital Management, LLC, along with Kevin Tang and several affiliated entities (Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc.), filed a Schedule 13G/A regarding their holdings in Altimmune, Inc. (ALT). The filing indicates that as of the event date on March 31, 2026, the reporting group collectively holds 666,022 shares of common stock, representing 0.3% of the company based on approximately 194.2 million shares outstanding. The shares are primarily held through Tang Capital Partners International, LP, with Tang Capital Management, LLC serving as the general partner and Kevin Tang as the manager. This filing marks an increase from a previous reported position of zero shares. The filing is classified under Rule 13d-1(c), certifying that the acquisition was not made for the purpose of changing or influencing the control of the issuer. Consequently, because the total ownership remains well below the 5% threshold, the importance is rated as low.